TARRYTOWN, N.Y., May 13, 2019 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Eylea (aflibercept) Injection to treat all stages of diabetic retinopathy (DR), and thereby…Original Article
FDA Approves Eylea (aflibercept) Injection for Diabetic Retinopathy
